MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

Published:2020-05 Issue:5 Volume:7 Page:e381-e394
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Raab Marc S,Engelhardt Monika,Blank Antje,Goldschmidt Hartmut,Agis Hermine,Blau Igor W,Einsele Hermann,Ferstl Barbara,Schub Natalie,Röllig Christoph,Weisel Katja,Winderlich Mark,Griese Janine,Härtle Stefan,Weirather Johannes,Jarutat Tiantom,Peschel Christian,Chatterjee Manik

Publisher

Elsevier BV

Subject

Hematology

Reference32 articles.

1. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update;Nijhof;Drugs,2018

2. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study;Kumar;Leukemia,2017

3. Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification;Schwonzen;Br J Haematol,1993

4. The splenic form of mantle cell lymphoma;Angelopoulou;Eur J Haematol,2002

5. CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients;Domingo-Domenech;Haematologica,2002

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phage display for discovery of anticancer antibodies;New Biotechnology;2024-11

2. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy;Kidney International Reports;2024-09

3. Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma;Cancers;2024-08-23

4. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection;New England Journal of Medicine;2024-07-11

5. Application of CD38 monoclonal antibody in kidney disease;Frontiers in Immunology;2024-05-10